10-Q · May 7, 2026
For Q4 2025, FDMT reported significant growth with revenue reaching $85 million, a notable increase from the previous quarter's $90,000 and surpassing analyst expectations of approximately $32.2 million. The company’s…
Earnings analysis · 10-Q
FDMT earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
4D Molecular Therapeutics remains a development-stage biotechnology company with no approved products and no product-sales revenue, while Q2 net loss increased to $72.9 million and diluted EPS was a loss of $1.04.…
Read full summary
4D Molecular Therapeutics remains a development-stage biotechnology company with no approved products and no product-sales revenue, while Q2 net loss increased to $72.9 million and diluted EPS was a loss of $1.04. Liquidity of $430.6 million supports planned operations for at least one year, and the company added a potential $200.0 million Hercules facility, but much of that borrowing capacity is conditional and secured by substantially all assets. Completion of wet AMD Phase 3 enrollment and regulatory designations are constructive operational developments, yet rising losses, continued financing needs, clinical execution risk and potential dilution support a bearish overall assessment.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.04
What stood out
-
Q2 revenue remained collaboration-driven
Q2 revenue was $3.781 million, primarily reflecting collaboration-related reimbursements, while diluted EPS was a loss of $1.04. The company has not generated product revenue from commercial sales.
-
Liquidity supports at least one year
Management reported $430.6 million of cash, cash equivalents and marketable securities as of June 30, 2026, which it believes funds planned operations for at least one year from the financial-statement issuance date.
-
Wet AMD Phase 3 enrollment completed
The company completed enrollment in both wet AMD Phase 3 studies of 4D-150, according to the associated quarterly update, advancing its lead program into a pivotal execution phase.
-
Added up to $200 million debt capacity
The Hercules Loan Agreement provides aggregate term loans of up to $200.0 million, with $20.0 million funded at closing and a stated maturity of June 1, 2031.
-
Lead program retains expedited-designation support
The FDA has granted RMAT designation for 4D-150 in wet AMD and DME, while 4D-150 was accepted into the EMA PRIME scheme for wet AMD. These designations may support regulatory interaction but do not assure approval.
-
No reported control deficiencies
Disclosure controls and procedures were concluded effective as of June 30, 2026, and management reported no change in internal control over financial reporting that materially affected, or was reasonably likely to materially affect, controls during the quarter.
What to watch
-
Losses and R&D cash burn are rising
Net loss increased to $72.9 million for the three months ended June 30, 2026, from $54.7 million in the prior-year quarter; the six-month loss was $141.7 million versus $102.6 million. Accumulated deficit reached $858.0 million.
-
Future financing remains necessary
The company had $430.6 million of cash, cash equivalents and marketable securities, but states it will require substantial additional capital in the future. Failure to raise funds could force it to delay, reduce or terminate development programs.
-
Debt availability is conditional
Only $20.0 million of the $200.0 million Hercules facility was funded at closing; $30.0 million is available only until June 15, 2027, $100.0 million depends on specified milestones, and $50.0 million is at Hercules' sole discretion.
-
Secured floating-rate debt adds constraints
The Loan Agreement is secured by substantially all assets, including intellectual property, and a hypothetical 75-basis-point rate increase would raise annual interest expense by approximately $0.2 million on the outstanding balance.
-
Foreign supplier and CRO exposure
The 10-Q identifies the U.S. BIOSECURE Act, enacted in December 2025, as potentially restricting work with certain biotechnology companies of concern; affected counterparties could increase costs or delay materials and services.
-
Potential dilution from pre-funded warrants
As of June 30, 2026, pre-funded warrants to purchase 16,935,665 common shares were outstanding and exercisable at a nominal price, creating potential dilution to voting power and earnings per share.
Management's outlook
No numeric revenue or EPS guidance was provided in the 10-Q. Management states that existing cash, cash equivalents and marketable securities will fund planned operations for at least one year from the issuance date of the financial statements; the filing also says the company expects no product-sales revenue for several years, if at all.
Earlier filings 4
10-K · March 18, 2026
4D Molecular Therapeutics positions itself as a late-stage genetic medicines company focused on retina (lead program 4D-150) and pulmonology (4D-710) using proprietary evolved AAV vectors. Operationally the company…
10-K · February 29, 2024
4D Molecular Therapeutics (4DMT) positions itself as a platform-driven, clinical-stage genetic medicines company building customized AAV vectors via its Therapeutic Vector Evolution platform ("approximately one billion…
10-Q · May 11, 2023
4D Molecular Therapeutics reported collaboration and license revenue of $298,000 for Q1 2023, down from $1,219,000 in Q1 2022. Net loss widened to $28.682 million (EPS -$0.88) from $26.338 million (EPS -$0.82) as…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.